I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.
I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.
I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH.IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,
I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.
THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.
PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..
I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.
I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.
THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS
THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!
Dystonia is a range of movement disorders that involve involuntary movements and extended muscle contractions. There may be twisting body movements, tremor, and unusual or awkward postures.
For some, the whole body may be involved in the movements, but for others, only certain parts of the body are affected. Sometimes, dystonia symptoms are linked to specific tasks, such as writing, as in writer's cramp.
Fast facts on dystonia
Dystonia is a neurological condition, affecting the brain and nerves. However, it does not impact cognitive abilities (intelligence), memory, and communication skills.
It tends to be a progressive condition, but this is not always the case.
Dystonia may be inherited, and one gene that plays a role has been identified. However, other causes have been identified, for instance, taking certain medications. Some diseases, such as some forms of lung cancer, can also produce signs and symptoms of dystonia.
Treatment may include dopamine or sedative-type medications. Sometimes, surgery can help.
Although most cases of dystonia start in people aged 40 to 60 years, it can affect all age groups.
What is dystonia?
Dystonia is a neurological condition, affecting the brain and nerves. However, it does not impact cognitive abilities (intelligence), memory, and communication skills.
It tends to be a progressive condition, but this is not always the case.
Dystonia may be inherited, and one gene that plays a role has been identified. However, other causes have been identified, for instance, taking certain medications. Some diseases, such as some forms of lung cancer, can also produce signs and symptoms of dystonia.
Treatment may include dopamine or sedative-type medications. Sometimes, surgery can help.
Although most cases of dystonia start in people aged 40 to 60 years, it can affect all age groups.
Symptoms
The symptoms of dystonia vary from mild to severe and can impact different parts of the body. The early symptoms include:
foot cramps
a "dragging leg"
uncontrollable blinking
difficulty speaking
involuntary pulling of the neck
Signs and symptoms vary depending on the type of dystonia they have. Below are some common examples:
Cervical dystonia
Cervical dystonia, also known as torticollis, is the most common form. It affects only one body part and generally starts later on in life. The neck muscles are affected most. Symptoms can include:
twisting of the head and neck
pulling forward of the head and neck
pulling backward of the head and neck
pulling sideways of the head and neck
Cervical dystonia can produce mild to severe symptoms. If muscle spasms and contractions are frequent and severe enough, the individual may also experience stiffness and pain.
Dystonia is not a single condition, but a range of disorders.
There are many causes of dystonia, including medications, oxygen
The muscles around the eyes are affected. Symptoms might include:
photophobia (sensitivity to light)
irritation in the eye(s)
excessive blinking, often uncontrollable
eyes close uncontrollably
People with severe symptoms may find it impossible to open their eyes for several minutes.
The majority of people with blepharospasm find that symptoms worsen as the day progresses.
Dopa-responsive dystonia
Dopa-responsive dystonia primarily affects the legs. Onset occurs from ages 5-30. This type of dystonia responds well to levodopa, a dopamine medication.
The most common symptom is a stiff, unusual walk, with the sole of the foot bent upwards. In some cases, the foot may turn outwards at the ankle.
Hemifacial spasm
The individual experiences spasms in the muscles on one side of the face. Symptoms may be more prominent when the individual is under mental stress or physically tired.
Laryngeal dystonia
The muscles in the voice box (larynx) spasm. People with laryngeal dystonia may sound very quiet and breathy when they speak, or strangled - depending on which way the muscle spasms (in or out).
Oromandibular dystonia
This type of dystonia affects the jaw and mouth muscles. The mouth can pull outwards and upwards.
Some individuals will only have symptoms when the muscles of the mouth and jaw are being used, while others may experience symptoms when the muscles are not in use. Some individuals may have dysphagia (problems swallowing).
Writer's cramp
Writer's cramp involves uncontrollable cramps and movements in the arm and wrist. This is a task-specific dystonia, because it affects people who do a lot of writing before symptoms appear.
Other task-specific dystonias
musician's cramp
typist's cramp
golfer's cramp
Generalized dystonia
Generalized dystonia normally affects children at the beginning of puberty. Symptoms generally occur in one of the limbs and eventually spread to other parts of the body.
Symptoms include:
Muscle spasms.
An abnormal, twisted posture, due to contractions and spasms in the limbs and torso.
A limb (or foot) may turn inwards.
Parts of the body may suddenly jerk rapidly.
Paroxysmal dystonia
In this rare version of dystonia, muscle spasms and abnormal body movements only happen at specific moments.
A paroxysmal dystonia attack can look like epilepsy during a seizure (fit). However, the individual does not lose consciousness and will be aware of their surroundings, unlike epilepsy. An attack can last for just a few minutes, but in some cases, may persist for several hours. The following triggers may bring on an attack:
Dystonia can be classified according to its underlying cause:
Primary dystonia - not related to another condition. No cause can be identified.
Secondary dystonia - related to genetics, a neurological change, or an injury.
Dystonia is also defined according to the body part(s) affected:
Focal dystonia - only one part of the body is affected.
Segmental dystonia - affects two or more connected regions of the body.
Multifocal dystonia - at least two unconnected regions of the body are affected.
Generalized dystonia - both legs and other regions of the body are affected.
Hemidystonia - half of the entire body is affected.
Causes
The causes of dystonia depend on whether it is primary or secondary.
Causes of primary dystonia
In primary dystonia, no underlying cause is identified. Experts believe it may be a problem with a part of the brain called the basal ganglia. This region is responsible for involuntary movements.
It may be that not enough, or the wrong types of neurotransmitters are produced in the basal ganglia, resulting in primary dystonia symptoms. It is also possible that enough is produced, but not the right type for proper muscle function. Researchers believe that other brain regions are also involved.
Some types of dystonia are linked to faulty genes.
Causes of secondary dystonia
This type of dystonia is caused by a combination of various conditions and diseases; for example:
Parkinson's disease is also a neurodegenerative condition that affects the same part of the brain as dystonia - the basal ganglia. Because of this, both conditions can sometimes appear in the same individual.
Drug induced dystonia
Certain drugs can cause dystonia. Cases of drug-induced dystonia normally occur after just one exposure to a drug. In general, this is relatively easy to treat successfully.
However, sometimes, dystonia can develop after taking a drug for some time, this is called tardive dystonia; Tardive dystonia is most commonly caused by drugs called neuroleptics, which are used to treat psychiatric, gastric, and movement conditions.
Levodopa - if symptoms improve rapidly after taking levodopa, the doctor will most likely diagnose early-onset dystonia.
Medication treatments
The following are common treatments for dystonia:
Levodopa
People diagnosed with dopa-responsive dystonia will be prescribed levodopa treatment. This medication raises levels of dopamine - a neurotransmitter. People taking levodopa may initially experience nausea, which should ease and disappear after the body gets used to the drug.
Botulinum toxin
This powerful poison, which is safe when administered in very small doses, is often used as a first-line treatment for most other types of dystonia. It prevents specific neurotransmitters from reaching the affected muscles, preventing spasms.
Botulinum toxin is administered by injection. One dose usually lasts about 3 months. There may be some initial (temporary) pain at the injection site.
Anticholinergics
These medications block the release of acetylcholine, a neurotransmitter known to cause muscle spasms in some types of dystonia. Anticholinergics may not always work.
Muscle relaxants
Muscle relaxants are usually prescribed if other treatments have not been effective. They raise the levels of GABA (gamma-aminobutyric acid), a neurotransmitter that relaxes muscles. Examples of muscle relaxants include diazepam and clonazepam. The medication can be administered by mouth or by injection.
Physical therapy
The following are common physical therapy treatments for dystonia.
Sensory tricks
Sometimes, symptoms can be relieved by touching the affected part of the body, or a body part near to it. Individuals with cervical dystonia may find that if they touch the back of their head or the side of their face, symptoms improve or go away completely.
Splints and braces may sometimes be used as part of a sensory trick therapy.
A physical therapist can also help them improve their posture. Good posture helps protect and strengthen muscles and tissues. Good posture may be achieved with an exercise program, and/or the use of braces.
Surgery
If other therapies have not been effective, the doctor may recommend surgery. Surgical procedures for dystonia include:
Selective peripheral denervation
Selective peripheral denervation is sometimes used for people with cervical dystonia. The surgeon makes an incision in the neck before cutting some of the nerve endings that are connected to affected muscles. After surgery, there is likely to be some loss of feeling in their neck.
Deep brain stimulation
Small holes are drilled into the skull. Tiny electrodes are threaded through the holes and placed in the globus pallidus, a part of the basal ganglia.
A small pulse generator is connected to the electrodes. The pulse generator is implanted under the skin, usually in the chest or lower abdomen. The pulse generator emits signals to the globus pallidus, which help block the abnormal nerve impulses produced by the basal ganglia.
There is not much information on the long-term beneficial or detrimental effects of deep brain stimulation because it is a fairly new technique. Deep stimulation results take time; it can sometimes be months before the effects become apparent.
WASHINGTON, D.C. — Congresswoman Elise Stefanik is among a bipartisan group urging Speaker of the House Paul Ryan to bring a bill to the floor that would allow more Vietnam vets to access benefits for Agent Orange-related illnesses.
Congressman David G. Valadao (CA-21) introduced H.R. 299, the Blue Water Navy Vietnam Veterans Act, last January to grant presumptive Agent Orange exposure status to U.S. service members who served in the territorial seas of Vietnam during the Vietnam War.
Stefanik is an original cosponsor of the legislation, which would enable eligible veterans to receive expedited consideration for Veterans Affairs benefits if they suffer from any of the diseases the U.S. Government has linked to Agent Orange.
"Our district is home to more veterans than any district in New York state, and our offices know firsthand the frustrations that the Blue Water Vets are facing trying to get the benefits they need and deserve,” Stefanik said in a statement.
“Our brave veterans served heroically, and we should never leave them behind. This legislation would ensure our Blue Water Navy Vietnam Veterans receive the benefits they are entitled to, and I urge Speaker Ryan and House Leadership to bring this bill up for a vote without delay.”
HEAVILY SUPPORTED
Currently, H.R. 299 has been cosponsored by 321 Members of Congress, nearly three quarters of the U.S. House of Representatives, and has received the support of almost every single veteran’s service organization.
“I am proud of the work that Congress has achieved under Speaker Ryan’s leadership and know he is a steadfast champion of veterans throughout our country," Valadao said in a statement.
"While I understand it is time to get our fiscal house in order, we must not balance our budget on the backs of America’s heroes."
TOXIC HERBICIDE
During the Vietnam War, more than 20 million gallons of the herbicide “Agent Orange” were sprayed to remove jungle foliage.
A toxic chemical in the herbicide has since been linked to devastating health effects, including non-Hodgkin’s lymphoma, various cancers, type II diabetes, and Parkinson’s disease.
The Agent Orange Act of 1991 empowered the secretary of Veterans Affairs to declare certain illnesses “presumptive” to exposure to Agent Orange and enabled veterans to receive disability compensation for these related conditions.
However, in 2002, the VA stopped giving benefits to blue water veterans and limited the scope of the Agent Orange Act to only those veterans who could provide proof of “boots on the ground” in Vietnam.
As a result, veterans who served in the waters off of the Vietnamese coast or in bays and harbors are required to file individual claims to restore their benefits, which are then decided on a case-by-case basis.
SAME PLAYING FIELD
Key provisions of H.R. 299 are:
• Restoration of the presumptive coverage for those who served in the territorial seas of Vietnam that existed prior to 2002 and lifting of the burden from the individual veteran to prove direct exposure to Agent Orange.
• Placing Navy personnel on the same playing field as those who served in-country, as the presumption currently exists only for veterans who served on land and inland waterways.
• Reduction of backlogged VA claims for veterans who are suffering from diseases the U.S. government has linked to Agent Orange, therefore reducing the overall VA backlog.
The great ice hockey player Wayne Gretzky once said “A good hockey player plays where the puck is. A great hockey player plays where the puck is going to be” (the original quote actually came from his father, Walter).
At the start of each year, it is a useful practise to layout what is planned for the next 12 months. This can help us better anticipate where ‘the puck’ will be, and allow us to prepare for things further ahead.
2017 was an incredible year for Parkinson’s research, and there is a lot already in place to suggest that 2018 is going to be just as good (if not better).
In this post, we will lay out what we can expect over the next 12 months with regards to the Parkinson’s-related clinical trials research of new therapies.
Many readers will be familiar with the name Warren Buffett.
The charming, folksy “Oracle of Omaha” is one of the wealthiest men in the world. And he is well known for his witticisms about investing, business and life in general.
He regularly provides great one liners like:
“We look for three things [in good business leaders]: intelligence, energy, and integrity. If they don’t have the latter, then you should hope they don’t have the first two either. If someone doesn’t have integrity, then you want them to be dumb and lazy”
“Work for an organisation of people you admire, because it will turn you on. I always worry about people who say, ‘I’m going to do this for ten years; and if I really don’t like it very much, then I’ll do something else….’ That’s a little like saving up sex for your old age. Not a very good idea”
“Choosing your heroes is very important. Associate well, marry up and hope you find someone who doesn’t mind marrying down. It was a huge help to me”
Mr Buffett is wise and a very likeable chap.
Few people, however, are familiar with his business partner, Charlie Munger. And Charlie is my favourite of the pair.
A college drop-out who served as a meteorologist in the US Army Air Corps, before going to Harvard to study Law. At age 31, he met Warren at a dinner and convinced him to go into investing. And the rest is history.
When it comes to the one lines, Charlie gets to the point colder and quicker than Warren. And it was Charlie who provided one particular pearl that I hold on to:
The secret to happiness is to lower your expectations.
Easy to say for a billionaire, do I hear you mutter?
Charlie is not for a moment suggesting that one should not be ambitious. Rather he is simply saying aim for the stars, but lower your expectations so that if you only reach the moon you won’t be disappointed. It would still be an amazing achievement.
I have taken Mr Munger’s quote one step further: I have no expectations.
My cup is completely empty. Thus, whenever anything happens, it’s magic! This particular strategy has served me well in scientific research where (if we are honest) few things ever seem to meet expectations.
Now, having said all this: I do have some expectations for 2018
They are based on things that we know are coming. For example:
Two new countries will emerge in the form of New Caledonia and Bougainville as they both hold independence referendums from France and Papua New Guinea.
The FIFA football world cup will be held in Russia
NASA will deploy the James Webb Space Telescope (which will be more powerful than the Hubble telescope)
The results of the phase II GDNF clinical trial from Bristol will be published (see below).
In this post we will outline the things we can expect from Parkinson’s clinical research in 2018 :
I am going to frame this discussion around a common theme that I had in many of my public talks last year with regards to what a ‘cure for Parkinson’s’ will look like, for example:
That theme was: any ‘cure for Parkinson’s’ is going to require three components:
A disease halting mechanism
A neuroprotective agent
Some form of cell replacement therapy
In this post we will explore each of these components individually and discuss what we should learn in 2018. Let’s look at the first component of any “Cure for Parkinson’s”:
1. A disease halting mechanism
Parkinson’s is a progressive neurodegenerative condition. Thus, the first and most critical component of any ‘cure’ for Parkinson’s involves a treatment that willslow down/halt that progressionof the condition.
This can be done either directly or indirectly.
The direct approach
You can think of the direct approach in military terms as a full frontal assault on the enemy. Going straight at the condition and trying to punch a hole through those enemy lines, which gets at the heart of the problem. A direct approach in halting Parkinson’s disease, however, requires a fundamental understanding of how the condition is actually progressing.
And if we are completely honest, we “are not there yet”. We do not know the mechanisms that underly the gradual progress of this condition. But fear not.
As Prof George Church recently pointed out in an excellent interview, “we developed effective smallpox prevention back when we had close to zero understanding of virology and immunology”.
Within the Parkinson’s field, we do have some good theories about how the condition may be spreading in the brain and they are worth testing while new ideas are being investigated.
One of those theories is the idea that a toxic form of the Parkinson’s-associated protein, alpha synuclein, could be being passed from cell to cell, and as it is absorbed by each new healthy cell it starts causing trouble which results in clustering of protein (leading to the appearance of Lewy bodies).
And there is some evidence for this as individuals who received cell transplants back in the 1990s have since passed away and their brains have been examined post-mortem. One very interesting finding from those brains is that some of the cells in the transplants up to 10% in one case – have Lewy bodies in them. This suggests that condition is being passed on from the Parkinson’s affected brain to the healthy transplanted cells in some way. Researchers have proposed that the alpha synuclein protein may be the guilty party in this process.
1.PD Nilotinib, which is being conducted at Georgetown University in Washington DC (Click here for the more details about this study). This study involves 75 participants and will involve two parts:In the first part of the study, one third of the participants receiving a low dose (150mg) of Nilotinib, another third receiving a higher dose (300mg) of Nilotinib and the final third will receive a placebo drug (a drug that has no bioactive effect to act as a control against the other two groups). The outcomes will be assessed clinically at six and 12 months by investigators who are blind to the treatment of each subject. These results will be compared to clinical assessments made at the start of the trial.In the second part of the study, there will be a one-year open-label extension trial, in which all participants will be randomised given either the low dose (150mg) or high dose (300mg) of Nilotinib. This extension is planned to start upon the completion of the first part (the placebo-controlled trial) to evaluate Nilotinib’s long-term effects.
NILO-PD, which is being conducted at the Feinburg School of Medicine at Northwestern University (Click here for the more details about this study). This study will involve two groups (or cohorts) of participants.The treatment will firstly be given to a first cohort of 75 people everyday for six months, during which the participants will be closely monitored. Following the treatment phase there will be an 8 week follow up period (during which all treatments are stopped), in order to determine Nilotinib’s safety and tolerability. Trial participants will be tested on their motor and cognitive abilities, and they will give sampled (i.e., blood and spinal fluid) for biological testing. All of these tests will provide the investigators with data with which to evaluate the potential impact of Nilotinib on Parkinson’s symptoms and the disease progression.If the drug is shown to be safe in this first cohort, a second trial is planned to be immediate initiated which would test Nilotinib in a second cohort of 60 people with early Parkinson’s disease. These subjects would be given the highest tolerated daily dose of Niltotinib (based on the results of the first study) or a placebo for 12 months. The same measurements (eg. biological samples) would be applied to this study as well.
Click here to read an SoPD post about Nilotinib and these clinical trials. Both of these studies are expected to provide results in 2020.
To review articles that says click on as well as see more information, please go to this:
In this video from Panorama Patient Network LLC, neurologist Susan Fox talks about some of the lifestyle changes people living with Parkinson’s disease can make to improve their quality of life.
Fox begins by explaining that exercise is one of the most important things a person with Parkinson’s disease can do to improve their life. There isn’t any particular exercise that’s better for Parkinson’s patients, but she advises people pick something they enjoy so they’ll be more likely to do it regularly.
Diet is also something Fox recommends people living with the condition look into. Eating a healthy balanced diet and drinking lots of water will help patients avoid gastrointestinal issues often associated with Parkinson’s, such as constipation, and will help medication work to its full potential.
Sleep is the final issue Fox addresses. Getting regular quality sleep where you feel refreshed upon waking can help the brain produce dopamine. And if you feel fatigued during the day, having a short nap can help restore energy.
###
Parkinsons’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
It has new software which can detect a side-effect of treatment that causes involuntary jerking movements, it was revealed last night.
Prolonged exposure to the dopamine replacement drugs used to treat Parkinson’s can lead to dyskinesia – involuntary jerking and spasms of the body.
Researchers at Heriot-Watt University in Edinburgh said the software reliably detects the condition.
They are now using their findings to develop a home monitor that will help clinicians adapt and improve treatment.
" The problem is that, as Parkinson’s disease
worsens over time, the dose required to
treat the motor features increases "
Dr Michael Lones - Associate professor of computer science at Heriot-Watt University
The motor features of Parkinson’s, such as tremor and postural instability, are caused by a lack of the chemical dopamine. About 90 per cent of patients treated with dopamine replacement drugs over 10 years reported dyskinesia symptoms.
Dr Lones and his team carried out two clinical studies with 23 patients who had all displayed evidence of dyskinesia.
“The clinical studies allowed us to capture and mine data about how patients move and used those to build models,” Dr Lones said.
“We developed our algorithm to make as few assumptions as possible. With traditional analysis, you make assumptions about what a movement looks like. If it doesn’t look like exactly that, you won’t detect it.
“The algorithm works by building a mathematical equation that describes patterns of acceleration which are characteristic of dyskinesia.
“The system then uses this equation to discriminate periods of dyskinesia from other movements, relaying this information to clinicians.”
They can then “adapt a patient’s medication as necessary and more effectively manage the side-effects, which currently reduce the quality of life for a great number of patients”.
The research was done in collaboration with York University and Leeds Teaching Hospitals NHS Trust.
Patients with Parkinson’s disease have more errors in the mitochondrial DNA within the brainstem, leading to increased cell death in that area, a new study has found. The researchers, from Newcastle and Sussex universities, also reported that surviving brain cells in the brainstem have more copies of mitochondrial DNA and this has not been identified before.
The study’s insights into Parkinson’s disease suggests a new target for therapies for patients with the debilitating condition. The findings are surprising, since the results differ from what has been seen in studies of brain regions that harbor other brain cell-types.
“Our study is a major step forwards in gaining an enhanced insight into the serious condition. Only by understanding the complexities of what happens in specific cell-types found in specific areas of the brain during this disease can targeted treatments for Parkinson’s disease be produced,”
said Dr. Joanna Elson, a mitochondrial geneticist at Newcastle University.
Pedunculopontine Nucleus Changes
Research shows that in Parkinson’s disease, a brainstem region called the pedunculopontine nucleus (PPN) develops changes in DNA found in mitochondria — the batteries of the cell — as they produce and store energy that cells can use.
This study looked at cholinergic neurons that are responsible for producing the brain chemical acetylcholine, which is released by cholinergic nerve cells to send signals from one neuron to another.
Death of these cells in the PPN is believed to be the cause of some of the symptoms of Parkinson’s disease, such as problems with attention, walking and posture. Identifying changes in the mitochondrial DNA in PPN cholinergic neurons has the potential to allow the development of more effective treatments targeted to specific cell-types.
The PPN is an understudied part of the brain. Researchers used post-mortem tissue from the Newcastle Brain Tissue Resource, based at Newcastle University, to isolate single neurons for in-depth analysis.
Targeted Parkinson’s Disease Treatment
Parkinson’s disease is a condition in which part of the brain becomes progressively damaged over many years. It is estimated that around one in 500 people in the UK are affected by the condition.
Dr. Ilse Pienaar, a neuroscientist at Sussex University, said:
“At present, treatments are aimed at the whole brain of patient’s with Parkinson’s disease. Only by understanding the complexities of what happens in specific cell-types found in specific areas of the brain during this disease can targeted treatments be produced. We believe that not only would cell-specific targeted treatments be more effective, but they would also be associated with fewer side-effects.”
The PPN was of interest because, in previous studies, patients with Parkinson’s disease displayed lower levels of mitochondrial DNA (mtDNA) in remaining dopaminergic neurons.
This study showed that mtDNA levels are higher in the surviving cholinergic neurons of the brainstem, but with both cell-types that undergo profound degeneration during Parkinson’s disease. The finding identifies how vulnerable cell groups react and respond differently to the accumulation of mitochondrial DNA damage seen in the disease, highlighting the need for cell-specific treatments.
The researchers are now aiming to continue with further research to investigate the findings and test the mechanisms by which targeted treatment could be delivered to patients.
Bury, A. G., Pyle, A., Elson, J. L., Greaves, L., Morris, C. M., Hudson, G. and Pienaar, I. S.